IPACT
Image-guided pancreatic cancer therapy
| Coordinatore | TECHNISCHE UNIVERSITEIT EINDHOVEN
Organization address
address: DEN DOLECH 2 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 8˙612˙064 € |
| EC contributo | 5˙991˙070 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-01-01 - 2017-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TECHNISCHE UNIVERSITEIT EINDHOVEN
Organization address
address: DEN DOLECH 2 contact info |
NL (EINDHOVEN) | coordinator | 1˙202˙326.00 |
| 2 |
IMASONIC SAS
Organization address
address: ZA RUE DES SAVOUROTS contact info |
FR (VORAY SUR L'OGNON) | participant | 1˙259˙050.00 |
| 3 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 1˙161˙600.00 |
| 4 |
PHILIPS ELECTRONICS NEDERLAND B.V.
Organization address
address: Boschdijk 525 contact info |
NL (EINDHOVEN) | participant | 1˙040˙459.00 |
| 5 |
NEAGEN OY
Organization address
address: KIRKKOKATU 12 contact info |
FI (OULU) | participant | 538˙500.00 |
| 6 |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
DE (MUENCHEN) | participant | 497˙400.00 |
| 7 |
Philips GmbH
Organization address
address: Luebeckertordamm 5 contact info |
DE (Hamburg) | participant | 195˙485.00 |
| 8 |
PHILIPS OY
Organization address
address: AYRITIE 4 contact info |
FI (VANTAA) | participant | 96˙250.00 |
| 9 |
PHILIPS TECHNOLOGIE GMBH
Organization address
address: LUEBECKERTORDAM 5 contact info |
DE (HAMBURG) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The aim of the iPaCT project is to address the unmet clinical need for an improved therapy of pancreatic cancer by developing a new integrated technology platform for image-guided thermal therapy. Yearly, 280000 new cases of pancreatic cancer are diagnosed worldwide. Being usually diagnosed late stage and without any efficient therapy available, basically all patients die with an average life expectancy of only a few months after diagnosis, leading to an overall low prevalence in society. Therefore, pancreatic cancer is a rare disease with an urgent clinical need for a new and improved therapeutic option.
A potential breakthrough solution for the treatment of pancreatic cancer can be found in thermal therapies using high intensity focused ultrasound (HIFU) combined with local, temperature-triggered drug delivery. We propose a novel US-MR-HIFU system that integrates HIFU with two imaging modalities, i.e. Magnetic Resonance Imaging (MRI) and diagnostic Ultrasound (US) for image guidance of thermal ablation (T=60â°C) and/or hyperthermia (T=42-43â°C) of pancreatic tumours. For image-guided drug delivery, new temperature-sensitive nanocarriers will be developed that provide a high local dose of chemotherapeutic drug. Multimodal (molecular) imaging information, simultaneously acquired using the US-MR-HIFU platform, provides motion compensated temperature feedback as well as visualization of perfusion and drug uptake in the target tissue allowing personalized therapy. The consortium, including two innovative SMEs (Imasonic, Neagen), two hospitals (Klinikum der Universität München and University Medical Center Utrecht), Eindhoven University of Technology and Philips (a medical device company), represents the total chain from technology development, preclinical testing to clinical translation guaranteeing a clear route for later clinical use and a route to market for the SMEs partners, leveraging the competencies and strengths of a leading global healthcare company.'
Altri progetti dello stesso programma (FP7-HEALTH)
EPIC-CVD (2012)
EPIC-CVD: Individualised CVD risk assessment: tailoring targeted and cost-effective approaches to Europe's diverse populations
Read MoreNILVAD (2012)
A European multicentre double-blind placebo-controlled phase III trial of nilvadIpine in mild to moderate Alzheimer’s disease
Read More